Media headlines about GenMark Diagnostics (NASDAQ:GNMK) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.9818226151436 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of GenMark Diagnostics (GNMK) traded up $0.07 on Thursday, hitting $4.46. The company’s stock had a trading volume of 152,600 shares, compared to its average volume of 470,094. GenMark Diagnostics has a twelve month low of $3.63 and a twelve month high of $13.67. The firm has a market cap of $240.55, a P/E ratio of -3.66 and a beta of 0.78. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12.

Several research analysts recently commented on GNMK shares. Canaccord Genuity reissued a “buy” rating and issued a $14.00 price objective on shares of GenMark Diagnostics in a research note on Monday, October 30th. Needham & Company LLC reduced their price objective on GenMark Diagnostics from $15.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 3rd. Raymond James Financial reaffirmed a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Cowen reaffirmed a “buy” rating and issued a $10.00 target price on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Finally, Zacks Investment Research downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $11.80.

In other GenMark Diagnostics news, insider Hany Massarany sold 6,584 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $4.37, for a total value of $28,772.08. Following the completion of the sale, the insider now directly owns 357,190 shares of the company’s stock, valued at approximately $1,560,920.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 21,836 shares of company stock valued at $100,151 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.

WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect GenMark Diagnostics (GNMK) Stock Price” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with's FREE daily email newsletter.